Disrupting the networks of cancer

Clinical Cancer Research

Volumn 18, Issue 10, 2012, Pages 2801-2808

  Camacho, Daniel F ^a   Pienta, Kenneth J ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR; CHEMOKINE; CYTOKINE; HORMONE; INTERLEUKIN 1; INTERLEUKIN 11; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEINASE; STROMAL CELL DERIVED FACTOR 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

CANCER CELL DESTRUCTION; CANCER PREVENTION; CANCER SURVIVAL; CELL INTERACTION; CELL MIGRATION; CELL NETWORK; CELLULAR PARAMETERS; CYTOKINE PRODUCTION; HOST CELL; HUMAN; METASTASIS; NUCLEAR NETWORK; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

CELL NUCLEUS; CHEMOKINES; CYTOKINES; HUMANS; METABOLIC NETWORKS AND PATHWAYS; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84861119813     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0366     Document Type: Review

References (58)

1. Smithers DW. An attack on cytologism. Lancet 1962;1:493-9.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
3. Jemal A, Bray F, CenterMM,Ferlay J, Ward E, FormanD. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
4. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100: 57-70. (Pubitemid 30046295)
5. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
6. Cavallo F, De Giovanni C, Nanni P, Forni G, Lollini PL. 2011: the immune hallmarks of cancer. Cancer Immunol Immunother 2011;60: 319-26.
7. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009;30:1073-81.
8. Pietras K, Ostman A. Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res 2010;316:1324-31.
9. Tansley AG. The use and abuse of vegetational concepts and terms. Ecology 1935;16:284-307.
10. Pienta KJ, McGregor N, Axelrod R, Axelrod DE. Ecological therapy for cancer: defining tumors using an ecosystem paradigm suggests new opportunities for novel cancer treatments. Transl Oncol 2008;1: 158-64.
11. Beltrao P, Cagney G, Krogan NJ. Quantitative genetic interactions reveal biological modularity. Cell 2010;141:739-45.
12. Mareel M, Constantino S. Ecosystems of invasion and metastasis in mammary morphogenesis and cancer. Int J Dev Biol 2011;55:671-84.
13. Ziogas DE, Katsios C, Roukos DH. From traditional molecular biology to network oncology. Future Oncol 2011;7:155-9.
14. Roychowdhury S, Iyer MK, Robinson DR, Lonigro RJ, Wu YM, Cao X, et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med 2011;3:111ra21.
15. Wilson DS. Complex interactions in metacommunities, with implications for biodiversity and higher levels of selection. Ecology 1992;73:1984-2000. (Pubitemid 23400157)
16. Leibold MA, Holyoak M, Mouquet N, Amarasekare P, Chase JM, Hoopes MF, et al. The metacommunity concept: a framework for multi-scale community ecology. Ecol Lett 2004;7:601-13. (Pubitemid 38847749)
17. Chen KW, Pienta KJ. Modeling invasion of metastasizing cancer cells to bone marrow utilizing ecological principles. Theor Biol Med Model 2011;8:36.
18. Pienta KJ, Loberg R. The "emigration, migration, and immigration" of prostate cancer. Clin Prostate Cancer 2005;4:24-30. (Pubitemid 41018179) (Pubitemid 41018179)
19. Comen E, Norton L, Massague J. Clinical implications of cancer selfseeding. Nat Rev Clin Oncol 2011;8:369-77.
20. Kim MY, Oskarsson T, Acharyya S, Nguyen DX, Zhang XHF, Norton L, et al. Tumor self-seeding by circulating cancer cells. Cell 2009;139: 1315-26.
21. Cirri P, Chiarugi P. Cancer-associated-fibroblasts and tumour cells: a diabolic liaison driving cancer progression. Cancer Metastasis Rev 2011 Nov 19. [Epub ahead of print].
22. Mareel M, Oliveira MJ, Madani I. Cancer invasion and metastasis: interacting ecosystems. Virchows Arch 2009;454:599-622.
23. Grisendi G, Bussolari R, Veronesi E, Piccinno S, Burns JS, De Santis G, et al. Understanding tumor-stroma interplays for targeted therapies by armed mesenchymal stromal progenitors: the Mesenkillers. Am J Cancer Res 2011;1:787-805.
24. Allen M, Louise Jones J. Jekyll and Hyde: the role of the microenvironment on the progression of cancer. J Pathol 2011;223:162-76.
25. Tyler AL, Asselbergs FW, Williams SM, Moore JH. Shadows of complexity: what biological networks reveal about epistasis and pleiotropy. Bioessays 2009;31:220-7.
26. Shiozawa Y, Pienta KJ, Taichman RS. Hematopoietic stem cell niche is a potential therapeutic target for bone metastatic tumors. Clin Cancer Res 2011;17:5553-8.
27. Hartwell LH, Hopfield JJ, Leibler S, Murray AW. From molecular to modular cell biology. Nature 1999;402:C47-52.
28. Tortora G, Bianco R, Daniele G, Ciardiello F, McCubrey JA, Ricciardi MR, et al. Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. Drug Resist Update 2007;10:81-100. (Pubitemid 47031052) (Pubitemid 47031052)
29. Kwak EL, Clark JW, Chabner B. Targeted agents: the rules of combination. Clin Cancer Res 2007;13:5232-7. (Pubitemid 47510344) (Pubitemid 47510344)
30. Allgayer H, Fulda S. An introduction to molecular targeted therapy of cancer. Adv Med Sci 2008;53:130-8.
31. Yasui H, Imai K. Novel molecular-targeted therapeutics for the treatment of cancer. Anticancer Agents Med Chem 2008;8:470-80.
32. Coffey DS, Getzenberg RH, DeWeese TL. Hyperthermic biology and cancer therapies: a hypothesis for the "Lance Armstrong effect".JAMA 2006;296:445-8. (Pubitemid 44127529) (Pubitemid 44127529)
33. Yamaguchi H, Hirakawa T, Inokuchi K. Importance of relative dose intensity in chemotherapy for diffuse large B-cell lymphoma. J Clin Exp Hematop 2011;51:1-5.
34. Fisher RI, Miller TP, O'Connor OA. Diffuse aggressive lymphoma. Hematology Am Soc Hematol Educ Program 2004:221-36.
35. Song SH, Han SW, Bang YJ. Epigenetic-based therapies in cancer: progress to date. Drugs 2011;71:2391-403.
36. Miller CP, Singh MM, Rivera-Del Valle N, Manton CA, Chandra J. Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors. J Biomed Biotechnol 2011;2011:514261.
37. Rosenzweig SA. Acquired resistance to drugs targeting receptor tyrosine kinases. Biochem Pharmacol 2012;83:1041-8.
38. Petrelli A, Giordano S. From single- to multi-target drugs in cancer therapy: When aspecificity becomes an advantage. Curr Med Chem 2008;15:422-32. (Pubitemid 351472408) (Pubitemid 351472408)
39. Takeuchi K, Ito F. Receptor tyrosine kinases and targeted cancer therapeutics. Biol Pharm Bull 2011;34:1774-80.
40. Bagnyukova TV, Serebriiskii IG, Zhou Y, Hopper-Borge EA, Golemis EA, Astsaturov I. Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents? Cancer Biol Ther [Review] 2010;10:839-53.
41. Weissman AM, Shabek N, Ciechanover A. The predator becomes the prey: regulating the ubiquitin system by ubiquitylation and degradation. Nat Rev Mol Cell Biol 2011;12:605-20.
42. Cvek B, Dvorak Z. The ubiquitin-proteasome system (UPS) and the mechanism of action of bortezomib. Curr Pharm Des 2011;17: 1483-99.
43. de Queiroz Crusoe E, Maiso P, Fernandez-Lazaro D, San-Segundo L, Garayoa M, Garcia-Gomez A, et al. Transcriptomic rationale for the synergy observed with dasatinib + bortezomib + dexamethasone in multiple myeloma. Ann Hematol 2012;91:257-69.
44. Jarvelainen H, Sainio A, Koulu M, Wight TN, Penttinen R. Extracellular matrix molecules: potential targets in pharmacotherapy. Pharmacol Rev 2009;61:198-223.
45. Grassian AR, Coloff JL, Brugge JS. Extracellular matrix regulation of metabolism and implications for tumorigenesis. Cold Spring Harb Symp Quant Biol 2011 Nov 21. [Epub ahead of print].
46. Bissell MJ, Hines WC. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med 2011;17:320-9.
47. Muranen T, Selfors LM, Worster DT, Iwanicki MP, Song L, Morales FC, et al. Inhibition of PI3K/mTOR leads to adaptive resistance in matrixattached cancer cells. Cancer Cell 2012;21:227-39.
48. Kleber M, Udi J, Metzke B, Terpos E, Roodmann GD, Morgan G, et al. Challenging the current approaches to multiple myeloma- and other cancer-related bone diseases: from bisphosphonates to targeted therapy. Leuk Lymphoma 2012 Jan 13. [Epub ahead of print].
49. Gaitskell K, Martinek I, Bryant A, Kehoe S, Nicum S, Morrison J. Angiogenesis inhibitors for the treatment of ovarian cancer. Cochrane Database Syst Rev 2011;9:CD007930.
50. Agarwala SS, Ribas A. Current experience with CTLA4-blocking monoclonal antibodies for the treatment of solid tumors. J Immunother 2010;33:557-69.
51. Axelrod R, Axelrod DE, Pienta KJ. Evolution of cooperation among tumor cells. Proc Natl Acad Sci U S A 2006;103:13474-9. (Pubitemid 44380132)
52. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006;124:263-6. (Pubitemid 43121975) (Pubitemid 43121975)
53. Kidd S, Spaeth E, Watson K, Burks J, Lu H, Klopp A, et al. Origins of the tumor microenvironment: quantitative assessment of adiposederived and bone marrow-derived stroma. PLoS One 2012;7: e30563.
54. Kycler W, Laski P. Surgical approach to pulmonary metastases from breast cancer. Breast J 2012;18:52-7.
55. Lee WS, Yun SH, Chun HK, Lee WY, Kim SJ, Choi SH, et al. Clinical outcomes of hepatic resection and radiofrequency ablation in patients with solitary colorectal liver metastasis. J Clin Gastroenterol 2008;42:945-9.
56. Loberg RD, Bradley DA, Tomlins SA, Chinnaiyan AM, Pienta KJ. The lethal phenotype of cancer: the molecular basis of death due to malignancy. CA Cancer J Clin 2007;57:225-41. (Pubitemid 47312082) (Pubitemid 47312082)
57. Akl EA, Gunukula S, Barba M, Yosuico VE, van Doormaal FF, Kuipers S, et al. Parenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. Cochrane Database Syst Rev 2011:CD006652.
58. Akl EA, Vasireddi SR, Gunukula S, Yosuico VE, Barba M, Terrenato I, et al. Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. Cochrane Database Syst Rev 2011:CD006466.